Patents Examined by John Edward Tarcza
-
Patent number: 4740461Abstract: Eucaryotic cells cotransformed with product and selection genes yield considerably greater quantities of product after a novel subcloning strategy is employed: Transformants are identified for product yield, cultured under selection pressure and the progeny screened for product yield. Novel transformation vectors contain directly ligated selection and product genes and/or eucaryotic promoters.Type: GrantFiled: December 27, 1983Date of Patent: April 26, 1988Assignee: Genetics Institute, Inc.Inventor: Randal J. Kaufman
-
Patent number: 4711848Abstract: Methods are provided for producing sites specific mutagenized alpha-1-antitrypsin. Particular mutants are formed having a mutation in the active site of alpha-1-antitrypsin at amino acid position 358 and at amino acid position 342.Type: GrantFiled: March 7, 1985Date of Patent: December 8, 1987Assignee: ZymoGenetics, Inc.Inventors: Margaret Y. Insley, Glenn Kawasaki
-
Patent number: 4693975Abstract: Somatic cell hybrids of purely human origin are described that are suitable fusion partners for producing hybridomas by fusion with antibody producing cells, which hybridomas are stable and continuous.Type: GrantFiled: November 20, 1984Date of Patent: September 15, 1987Assignee: The Wistar InstituteInventors: Danuta Kozbor, Carlo M. Croce
-
Patent number: 4691010Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 10% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8Ul myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.Type: GrantFiled: August 9, 1984Date of Patent: September 1, 1987Assignee: Ortho Pharmaceutical CorporationInventors: Patrick C. Kung, Gideon Goldstein
-
Patent number: 4661453Abstract: A process for the production of a tissue plasminogen activator obtained from cultured rat prostate adenocarcinoma cells. The techniques described lead to enhanced production of the tissue plasminogen activator for markedly prolonged periods of time. The tissue plasminogen activator so produced may be used for the treatment of thrombosis.Type: GrantFiled: June 19, 1984Date of Patent: April 28, 1987Assignee: American Biogenetic Sciences, Inc.Inventor: Morris Pollard
-
Patent number: 4659660Abstract: Antibiotic A47934 is produced by submerged, aerobic fermentation of new Streptomyces toyocaensis NRRL 15009. The antibiotic is active against gram-positive bacteria in vitro and in vivo. It promotes growth in poultry and swine and serves to enhance feed efficiency in ruminant animals having a developed rumen.Type: GrantFiled: June 3, 1985Date of Patent: April 21, 1987Assignee: Eli Lilly and CompanyInventors: Robert L. Hamill, Ralph E. Kastner
-
Patent number: 4657868Abstract: A biologically active substance is incorporated in a unitary body with a magnetically responsive material for carrying out diffusion testing. These may be, microbiological, immunological, serological and other biochemical examinations. The body is applied against a substrate or medium by application of an external magnetic field and a reaction region is produced at the site of the body and is measured by means of a reader. In order to insure deposit of the body on the substrate a predetermined location and corresponding reading of the reaction region at such location, the support for the substrate and the dispenser and rear are provided with suitable releasable coupling and orienting devices such that the dispenser and reader can be respectively engaged and oriented on the support in predetermined secured positions.Type: GrantFiled: September 29, 1982Date of Patent: April 14, 1987Inventor: Rolf Saxholm
-
Patent number: 4652599Abstract: A cell system is disclosed for the reproducible detection and isolation of human T-lymphotropic retroviruses (HTLV-family) with cytopathic effects (HTLV-III) from patients with the acquired immune deficiency syndrome (AIDS), pre-AIDS and in healthy carriers. One neoplastic aneuploid T-cell line derived from an adult with lymphoid leukemia, and termed HT, was susceptible to infection with HTLV-III, which is transformed and provides T-cell populations which are highly susceptible to and permissive for HTLV-III, and convenient for large scale production, isolation, and biological detection of the virus. Other operational neoplastic T-cell lines which are positive for OKT4 marker, e.g., Molt 3, CEM, Ti7.4 and HUT78, can produce HTLV-III in a large amount and retain its unlimited capability for growth.Type: GrantFiled: August 24, 1984Date of Patent: March 24, 1987Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Robert C. Gallo, Mikulas Popovic
-
Patent number: 4650764Abstract: A helper cell for providing retrovirus protein which is required by a normally replication incompetent recombinant retrovirus gene sequence in order to replicate is disclosed. In one embodiment there is a eukaryotic host cell, a first retrovirus gene sequence in the cell which has a helper portion coding for a retrovirus protein and which is capable of expressing the retrovirus protein, and a defective portion which renders the gene sequence replication imcompetent. In this embodiment, there is also a second retrovirus gene sequence in the cell having a defective retrovirus portThis invention was made with Government support under NIH Grant Nos. P01 CA 22443, P30 CA0 7175 and T32 CA0 9075 awarded by the Department of Health and Human Services. The Government has certain rights in this invention.Type: GrantFiled: March 26, 1984Date of Patent: March 17, 1987Assignee: Wisconsin Alumni Research FoundationInventors: Howard M. Temin, Shinichi Watanabe
-
Patent number: 4647773Abstract: A cell system is disclosed for the reproducible detection and isolation of human T-lymphotropic retroviruses (HTLV-family) with cytopathic effects (HTLV-III) from patients with the acquired immune deficiency syndrome (AIDS), pre-AIDS and in healthy carriers. One neoplastic aneuploid T-cell line derived from an adult with lymphoid leukemia, and termed HT, was susceptible to infection with the new variants of HTLV, which are transformed and providing T-cell populations which are highly susceptible and permissive from HTLV-III, and convenience for large scale production, isolation and biological detection of the virus.Type: GrantFiled: April 23, 1984Date of Patent: March 3, 1987Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Robert C. Gallo, Mikulas Popovic
-
Patent number: 4634664Abstract: Hybridoma cell line made by fusing a xenogeneic hybridoma cell to a genetically compatible substance producing cell. Such hybridomas can be used i.a. for the production of antibodies.Type: GrantFiled: January 20, 1983Date of Patent: January 6, 1987Assignee: Sandoz Ltd.Inventor: Lars Oestberg
-
Patent number: 4624925Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 10% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.Type: GrantFiled: October 4, 1982Date of Patent: November 25, 1986Assignee: Ortho Pharmaceutical CorporationInventors: Patrick C. Kung, Gideon Goldstein
-
Patent number: 4624921Abstract: A 6-thioguanine-resistant subvariant of the EBV-transformed human lymphoblastoid B cell line WI-L2 is described. The subvariant line, designated LTR228, fuses efficiently with human cells. Human.times.human hybridomas derived from LTR228 that produce monoclonal antibodies against tetanus toxin and blood group A are exemplified.Type: GrantFiled: April 26, 1984Date of Patent: November 25, 1986Assignee: Cetus CorporationInventors: James W. Larrick, Andrew R. Raubitschek, Kenneth E. Truitt
-
Patent number: 4623622Type: GrantFiled: January 25, 1983Date of Patent: November 18, 1986Assignee: Eleanor Roosevelt Institute for Cancer Research, Inc.Inventor: David W. Anderson
-
Patent number: 4614720Abstract: Hybrid cell line for production of monocloral antibody to an antigen found on essentially all normal human T cells and on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.Type: GrantFiled: October 4, 1982Date of Patent: September 30, 1986Assignee: Ortho Pharmaceutical CorporationInventors: Patrick C. Kung, Gideon Goldstein
-
Patent number: 4612282Abstract: Monoclonal antibodies demonstrating a reactivity with human breast cancer are produced. The hybridoma cultures secreting immunoglobins are produced by hydridoma technology. Splenic lymphocytes of mice, immunized with membrane-enriched fractions of metastatic human mammary carcinoma tissue are fused with the NS-1 non-immunoglobulin-secreting murine myeloma cell line. Screening of immunoglobulin reactivities and double cloning of cultures yielded 11 monoclonal antibodies that demonstrated activities with the surface of human mammary tumor cells and not with the surface of apparently normal human tissues. These monoclonal antibodies aid in the diagnosis, prognosis and treatment of human breast cancer.Type: GrantFiled: March 1, 1985Date of Patent: September 16, 1986Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Jeffrey Schlom, David Colcher, Marianna Nuti, Patricia H. Hand, Faye Austin
-
Patent number: 4608341Abstract: A fast growing, continuous, functional rat thyroid cell strain, FRTL-5, which maintains functional characteristics of iodide uptake and thyroglobulin synthesis over prolonged periods of culture is cloned from FRTL cells obtained from primary cultures of Fischer rat thyroid glands. The FRTL-5 cells are cultured in a medium containing approximately 5 percent calf serum supplemented with a mixture of hormones, at least one of which is thyrotropin.The FRTL-5 cells are employed in a series of assays which measure thyroid stimulatory or inhibitory factors. The FRTL-5 system of assay specifically measures thymidine incorporation, cAMP elevation and iodide uptake and permits the evaluation of patient sera, particularly those afflicted with Graves' disease and other autoimmune thyroid diseases, thereby providing a means for determining appropriate methods of treatment.Type: GrantFiled: May 31, 1983Date of Patent: August 26, 1986Assignee: Interthyr Research Foundation, Inc.Inventor: Francesco S. Ambesi-Impiombato
-
Patent number: 4598042Abstract: An immunoassay uses an antibody or antigen -enzyme conjugate which converts a precursor to a cycling agent used in a cycling detection system. The amount of cycling agent is continually increased permitting amplification. The prefered system converts NADP to NAD using the conjugate label and the cycling system interconverts NAD and NADH.Type: GrantFiled: December 8, 1983Date of Patent: July 1, 1986Inventor: Colin H. Self
-
Patent number: 4595655Abstract: The present invention provides a method for determining a ligand or receptor which comprises carrying out an assay for the ligand or receptor, the assay requiring a labelled component, wherein the labelled component is a conjugate between a ligand or a receptor and a primary enzyme that is itself capable of producing or removing a modulator for a secondary system or that is the first enzyme in an enzyme system that is capable of producing or removing a modulator for a secondary system, and determining that portion of labelled component to be determined by allowing the primary enzyme and any other enzymes in the enzyme system, to produce or remove the modulator for the secondary system, allowing the secondary system to function in the presence or absence as appropriate of the modulator, and determining a product of the secondary system.Type: GrantFiled: December 9, 1982Date of Patent: June 17, 1986Inventor: Colin H. Self
-
Patent number: 4594325Abstract: Human lymphoblastoid cell line capable of acting as a fusion partner in the preparation of hybridomas is grown and selected under conditions whereby a cell line is obtained having greatly enhanced fusion efficiency over the parent cell line. The cell line is derived from UC 729 by growing in Iscove's modified serum-free medium with plating at relatively high densities, followed by cloning at limiting dilutions and selecting for high frequency fusion.The subject cell line referred to as WI-L2-729 HF.sub.2 has the A.T.C.C. designation number CRL 8062, having been deposited on Apr. 2, 1981.Type: GrantFiled: March 26, 1981Date of Patent: June 10, 1986Assignee: The Regents of the University of Calif.Inventor: Robert L. Lundak